{{medical}}
{{Drugbox
| verifiedrevid = 464382551
| IUPAC_name = 6-(trifluoromethoxy)benzothiazol-2-amine
| image = Riluzole2DACS.svg
| width = 200
| image2 = Riluzole3DanBS.gif
| width2 = 200

<!--临床数据-->
| tradename = Rilutek
| Drugs.com = {{drugs.com|monograph|riluzole}}
| MedlinePlus = a696013
| licence_US = Riluzole
| pregnancy_AU = B3
| pregnancy_US = C
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx Only
| routes_of_administration = Oral

<!--药品数据-->
| bioavailability = 60±18%<ref name = TGA>{{cite web|title=PRODUCT INFORMATION RILUTEK® (riluzole) Tablets|work=TGA eBusiness Services|publisher=sanofi-aventis australia pty ltd|date=6 January 2009|accessdate=18 February 2014|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05951-3|format=PDF}}</ref>

| protein_bound = 97%<ref name = TGA/>
| metabolism = [[Hepatic|Hepatic]] ([[CYP1A2|CYP1A2]])<ref name = TGA/>
| elimination_half-life = 9-15 hours<ref name = TGA/> 
| excretion = Urine (90%)<ref name = TGA/>

<!--号码-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1744-22-5
| ATC_prefix = N07
| ATC_suffix = XX02
| ATC_supplemental =  
| PubChem = 5070
| IUPHAR_ligand = 2326
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00740
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4892
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7LJ087RS6F
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00775
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 744

<!--化学数据-->
| C=8 | H=5 | F=3 | N=2 | O=1 | S=1 
| molecular_weight = 234.199 g/mol
| smiles = FC(F)(F)Oc1ccc2nc(sc2c1)N
| InChI = 1/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
| InChIKey = FTALBRSUTCGOEG-UHFFFAOYAB
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = FTALBRSUTCGOEG-UHFFFAOYSA-N
}}
'''利鲁唑'''是[[赛诺菲|赛诺菲]]推出的一种用来治疗[[肌萎缩性脊髓侧索硬化症|肌萎缩性脊髓侧索硬化症]]的[[药物|药物]]。在部分[[病人|病人]]体内它可以延迟病人依靠[[医用呼吸机|医用呼吸机]]或进行[[氣管切開術|氣管切開術]]的时间，因此可以延长约两至三个月的病人生命<ref name = Coch>{{cite journal|last=Miller|first=RG|coauthors=Mitchell, JD; Moore, DH|title=Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).|journal=The Cochrane Database of Systematic Reviews|date=14 March 2012|volume=3|pages=CD001447|doi=10.1002/14651858.CD001447.pub3|pmid=22419278|url=http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001447.pub3/pdf|format=PDF}}</ref>。

==医学应用==
===肌萎缩性脊髓侧索硬化症===
一些迹象表明使用的剂量越高，对病人的改善越好，但是由于此药每片的价格很高，而其益处有限，因此大量用药的昂贵不一定值。一份荷兰的研究认为利鲁唑在男子体内和在女子体内的代谢不同，另外[[吸烟|吸烟]]或使用[[奥美拉唑|奥美拉唑]]降低病人[[血清|血清]]里利鲁唑的浓度<ref>{{cite journal|last=van Kan|first=HJ|coauthors=Groeneveld, GJ; Kalmijn, S; Spieksma, M; van den Berg, LH; Guchelaar, HJ|title=Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis.|journal=British Journal of Clinical Pharmacology|date=2005年3月|volume=59|issue=3|pages=310–3|pmid=15752377|pmc=1884790 |doi=10.1111/j.1365-2125.2004.02233.x|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884790/pdf/bcp0059-0310.pdf|format=PDF}}</ref>。一份回顾说病人延长一年生命的可能性为9%<ref name = Coch/>。

===心理治疗使用===
一些近来的研究认为利鲁唑可能对情绪失常和[[焦虑症|焦虑症]]有用<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958461/ Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder]. J Child Adolesc Psychopharmacol. 2010年8月; 20(4): 309–315.</ref>。针对[[重性抑郁障碍|重性抑郁障碍]]它有[[抗抑郁药|抗抑郁药]]的性能<ref>{{cite journal|last=Zarate CA|first=Jr|coauthors=Payne, JL; Quiroz, J; Sporn, J; Denicoff, KK; Luckenbaugh, D; Charney, DS; Manji, HK|title=An open-label trial of riluzole in patients with treatment-resistant major depression.|journal=The American Journal of Psychiatry|date=2004年1月|volume=161|issue=1|pages=171–4|pmid=14702270|doi=10.1176/appi.ajp.161.1.171}}</ref>。针对[[强迫症|强迫症]]<ref>{{cite journal|last=Coric|first=V|coauthors=Taskiran, S; Pittenger, C; Wasylink, S; Mathalon, DH; Valentine, G; Saksa, J; Wu, YT; Gueorguieva, R; Sanacora, G; Malison, RT; Krystal, JH|title=Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.|journal=Biological psychiatry|date=2005年9月1日|volume=58|issue=5|pages=424–8|pmid=15993857|doi=10.1016/j.biopsych.2005.04.043}}</ref>和[[广泛性焦虑症|广泛性焦虑症]]<ref>{{cite journal|last=Mathew|first=SJ|coauthors=Amiel, JM; Coplan, JD; Fitterling, HA; Sackeim, HA; Gorman, JM|title=Open-label trial of riluzole in generalized anxiety disorder.|journal=The American Journal of Psychiatry|date=2005年12月|volume=162|issue=12|pages=2379–81|pmid=16330605|doi=10.1176/appi.ajp.162.12.2379}}</ref>它有抑止作用。

==副作用==
非常常见（可能性〉10%）<ref name = MSR>{{cite web|title=Rilutek (riluzole) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|accessdate=18 February 2014|url=http://reference.medscape.com/drug/rilutek-riluzole-343067#showall}}</ref>：
*晕眩
*虚弱
*肺功能降低

常见（可能性在1-10%之间）<ref name = AMH>{{cite isbn|9780980579093}}</ref>：
*头痛
*头晕
*睡意
*呕吐
*腹痛
*转氨酶增高

不常见（可能性在0.1至1%之间）<ref name = AMH/>：
*[[胰腺炎|胰腺炎]]
*[[間質性肺病|間質性肺病]]

少见（可能性低于0.1%）<ref name = AMH/>：
*[[嗜中性白血球低下|嗜中性白血球低下]]
*过敏

===禁忌===
在以下情况下禁用：已知对利鲁唑及药片内其它成文反应敏感、肝病、怀孕或正在哺乳<ref name = TGA/>。

===反应===
由于利鲁唑的代谢需要[[CYP1A2|CYP1A2]]，这个细胞色素的基底、抑止剂和诱导剂可能和利鲁唑相互作用。

===过量===
过量的症状包括：神经和心理症状、急性脑中毒昏迷、昏迷和[[正鐵血紅蛋白血症|正鐵血紅蛋白血症]]。紧急使用亚甲蓝可以迅速回转严重正鐵血紅蛋白血症<ref name = TGA/>。

==原理==
利鲁唑抑制与被损伤的[[神经|神经]]有关的对[[河豚毒素|河豚毒素]]敏感的[[钠通道|钠通道]]<ref>{{cite journal|last=Song|first=JH|coauthors=Huang, CS; Nagata, K; Yeh, JZ; Narahashi, T|title=Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels.|journal=The Journal of Pharmacology and Experimental Therapeutics|date=1997年8月|volume=282|issue=2|pages=707–14|pmid=9262334|url=http://jpet.aspetjournals.org/content/282/2/707.full.pdf|format=PDF}}</ref><ref>{{cite journal|last=Bellingham|first=MC|title=A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?|journal=CNS Neuroscience & Therapeutics|date=2011年2月|volume=17|issue=1|pages=4–31|doi=10.1111/j.1755-5949.2009.00116.x|pmid=20236142}}</ref>。利鲁唑与谷氨酸受体之间的相互作用有争议，至今为止没有任何已知的受体和它结合<ref>{{cite journal|last=Wokke|first=J|title=Riluzole.|journal=Lancet|date=1996年9月21日|volume=348|issue=9030|pages=795–9|pmid=8813989|doi=10.1016/S0140-6736(96)03181-9}}</ref>。由于它抗谷氨酸的反应在钠通道被抑制的情况下依然可以被观察到，其原理与钠通道是否有关不明。它刺激谷氨酸吸收的作用似乎是它的大多数效应的原因<ref>{{cite journal |author=Azbill, RD; Mu, X; Springer, JE |title=Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes |journal=Brain Res. |volume=871 |issue=2 |pages=175–80 |date=2000年7月|pmid=10899284 |url=http://linkinghub.elsevier.com/retrieve/pii/S0006-8993(00)02430-6 |doi=10.1016/S0006-8993(00)02430-6}}</ref><ref>{{cite journal |author=Dunlop, J; Beal McIlvain, H; She, Y; Howland, DS |title=Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis |journal=J Neurosci. |volume=23 |issue=5 |pages=1688–96 |date=2003年3月1日|pmid=12629173 |url=http://www.jneurosci.org/cgi/pmidlookup?view=long&pmid=12629173 }}</ref>。除了它清除突触的谷氨酸外它可能也防止突触终端释放谷氨酸<ref>{{cite journal|last=Wang|first=S.-J|title=Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes)|journal=Neuroscience|date=2004年1月|volume=125|issue=1|pages=191–201}}</ref>。这些效应一起可以大量地降低谷氨酸信号和间接地导致它对谷氨酸的抑制作用。

==参考资料==
{{Reflist|2}}

==外部链接==
* 英国对利鲁唑的使用推荐 [https://web.archive.org/web/20051105131550/http://www.nice.org.uk/page.aspx?o=14491]
* 生产商网页 [http://www.rilutek.com]  
* [https://web.archive.org/web/20121206111610/http://www.meds-help.com/riluzole/ Riluzole] 病人信息

{{OCD pharmacotherapies}}

[[分类:N-甲基-D-天冬氨酸受体拮抗剂|分类:N-甲基-D-天冬氨酸受体拮抗剂]]
[[分类:有机氟化合物|分类:有机氟化合物]]
[[Category:三氟甲基化合物|Category:三氟甲基化合物]]